Jeil Pharmaceutical has completely reorganized its Central Research Institute, appointing experts in new drug development to key positions. The company aims to enhance its proprietary drug pipeline by shifting from a function-based research structure to a project-centered approach, integrating biological and artificial intelligence (AI) capabilities.
On November 1, Jeil Pharmaceutical announced the restructuring of its Central Research Institute and appointed Park Jun-seok, who joined the company in June, as the new head of the institute. Seong Gi-sa was appointed as the head of the Innovative Drug Center, and Kim Hye-jung was named the head of the Innovative Drug Team.
The core of this reorganization is the transition from three existing divisions to two centers. The previous structure, which included the New Drug Research Division, Pharmacotoxicology Research Division, and Synthesis Research Division, has been divided into the Innovative Drug Center and the Synthesis Research Center.
The Innovative Drug Center will focus on discovering new drug candidates by integrating medicinal chemistry with cell and animal-based pharmacology research. The Synthesis Research Center will enhance its capabilities in drug manufacturing and quality control (CMC) by adding early formulation research to its existing synthesis and process research.
A new non-clinical research team has been established under the direct supervision of the institute head, integrating toxicology research functions. The research support team has also been reorganized into a research management team, strengthening its research quality assurance (QA) capabilities to improve global technology exports and regulatory compliance.
Park Jun-seok, the new head of the Central Research Institute, has led the development of Korea's 34th new drug, 'Pexuclu,' and the 36th new drug, 'Enblo.' He has previously served as the head of the New Drug Discovery Center at Daewoong Pharmaceutical and as the Chief Strategy Officer (CSO) at Ianthe Therapeutics, with nearly 30 years of experience in drug candidate discovery and research and development.
Seong Gi-sa, who leads the Innovative Drug Center, is an expert with over 20 years of experience in cancer biology research. He has worked in new drug development at the U.S. targeted protein degradation (TPD) company Abivax and has led the discovery of molecular glue (MGD) candidates at domestic biotech firms.
Jeon Seong-hyun, who has overseen the Synthesis Research Division, has been appointed as the head of the Synthesis Research Center. He has been responsible for synthetic drug research and process development for 30 years.
The company has also recruited talent in the AI field. Kim Hye-jung, who has joined as the head of the Innovative Drug Team, is an expert in AI-based drug development and molecular design. She has previously served as the head of the foundational technology team at C&C New Drug Research Institute and as the head of the Innovative Drug Center at HK Inno.N. Notably, during her tenure, she successfully exported a candidate substance for atopic dermatitis treatment to the global pharmaceutical company Leo Pharma.
Park Jun-seok stated, "Through the new research organization, we will create the world's first innovative new drug and achieve success in global technology exports."
On November 1, Jeil Pharmaceutical announced the restructuring of its Central Research Institute and appointed Park Jun-seok, who joined the company in June, as the new head of the institute. Seong Gi-sa was appointed as the head of the Innovative Drug Center, and Kim Hye-jung was named the head of the Innovative Drug Team.
The core of this reorganization is the transition from three existing divisions to two centers. The previous structure, which included the New Drug Research Division, Pharmacotoxicology Research Division, and Synthesis Research Division, has been divided into the Innovative Drug Center and the Synthesis Research Center.
The Innovative Drug Center will focus on discovering new drug candidates by integrating medicinal chemistry with cell and animal-based pharmacology research. The Synthesis Research Center will enhance its capabilities in drug manufacturing and quality control (CMC) by adding early formulation research to its existing synthesis and process research.
A new non-clinical research team has been established under the direct supervision of the institute head, integrating toxicology research functions. The research support team has also been reorganized into a research management team, strengthening its research quality assurance (QA) capabilities to improve global technology exports and regulatory compliance.
Park Jun-seok, the new head of the Central Research Institute, has led the development of Korea's 34th new drug, 'Pexuclu,' and the 36th new drug, 'Enblo.' He has previously served as the head of the New Drug Discovery Center at Daewoong Pharmaceutical and as the Chief Strategy Officer (CSO) at Ianthe Therapeutics, with nearly 30 years of experience in drug candidate discovery and research and development.
Seong Gi-sa, who leads the Innovative Drug Center, is an expert with over 20 years of experience in cancer biology research. He has worked in new drug development at the U.S. targeted protein degradation (TPD) company Abivax and has led the discovery of molecular glue (MGD) candidates at domestic biotech firms.
Jeon Seong-hyun, who has overseen the Synthesis Research Division, has been appointed as the head of the Synthesis Research Center. He has been responsible for synthetic drug research and process development for 30 years.
The company has also recruited talent in the AI field. Kim Hye-jung, who has joined as the head of the Innovative Drug Team, is an expert in AI-based drug development and molecular design. She has previously served as the head of the foundational technology team at C&C New Drug Research Institute and as the head of the Innovative Drug Center at HK Inno.N. Notably, during her tenure, she successfully exported a candidate substance for atopic dermatitis treatment to the global pharmaceutical company Leo Pharma.
Park Jun-seok stated, "Through the new research organization, we will create the world's first innovative new drug and achieve success in global technology exports."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.